{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:24:00Z","timestamp":1777418640915,"version":"3.51.4"},"reference-count":77,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T00:00:00Z","timestamp":1276560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of colesevelam hydrochloride for the treatment of hypercholesterolemia and type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Literature retrieval was accessed through MEDLINE\/PubMed (1950\u2013March 2010), Web of Science (1980\u2013March 2010), and International Pharmaceutical Abstracts (1977\u2013March 2010) using the terms colesevelam, dyslipidemia, hypercholesterolemia, and type 2 diabetes mellitus. References from publications identified were reviewed for additional resources. In addition, abstracts presented at the most recent (2009) American Diabetes Association, American Association of Clinical Endocrinologists, and European Association for the Study of Diabetes annual meetings were searched for relevant original research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All articles in English identified from the data sources were evaluated. All relevant studies evaluating the safety and efficacy of colesevelam in hypercholesterolemia and\/or type 2 diabetes mellitus were included. Priority was placed on data obtained from human randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Seventeen clinical trials were reviewed and evaluated. Of the clinical trials evaluating colesevelam in hypercholesterolemia, 3 evaluated monotherapy, 4 evaluated combination therapy with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and 6 evaluated combination therapy with other lipid-lowering therapies. In the type 2 diabetes mellitus trials, colesevelam was evaluated in combination with metformin, sulfonylureas, insulin, and rosiglitazone and sitagliptin. A review of the clinical trials provided evidence that colesevelam monotherapy effectively reduces low-density lipoprotein cholesterol (LDL-C). Additionally, the use of colesevelam in combination with other lipid-lowering therapies further reduces LDL-C. Colesevelam also effectively reduces hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      in patients with type 2 diabetes mellitus. The safety and tolerability of colesevelam appear to be improved from that of older-generation bile acid sequestrants, with adverse effects similar to those with placebo in monotherapy and type 2 diabetes mellitus trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Colesevelam is a safe and effective option for the treatment of hypercholesterolemia and type 2 diabetes mellitus. It can fulfill a useful role in combination with HMG-CoA reductase inhibitors for hypercholesterolemia and should be considered in patients with type 2 diabetes mellitus with concomitant hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1m728","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T23:03:14Z","timestamp":1276642994000},"page":"1196-1206","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus"],"prefix":"10.1177","volume":"44","author":[{"given":"Luigi","family":"Brunetti","sequence":"first","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Somerville, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn R","family":"Hermes-DeSantis","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,6,15]]},"reference":[{"key":"bibr1-aph.1M728","unstructured":"KungHC, HoyertDL, XuJ, MurphySL. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120. www.cdc.gov\/nchs\/data\/nvsr\/nvsr56\/nvsr56_10.pdf"},{"key":"bibr2-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191261"},{"key":"bibr3-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"bibr4-aph.1M728","doi-asserted-by":"crossref","unstructured":"Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, I: reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. DOI 10.1001\/jama.251.3.351","DOI":"10.1001\/jama.251.3.351"},{"key":"bibr5-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"bibr6-aph.1M728","first-page":"2545","volume":"358","author":"Gerstein HC","year":"2008","journal-title":"Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med"},{"key":"bibr7-aph.1M728","first-page":"2560","volume":"358","author":"Patel A","year":"2008","journal-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med"},{"key":"bibr8-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808431"},{"key":"bibr9-aph.1M728","doi-asserted-by":"crossref","unstructured":"MontoriVM, Fernandez-BasellsM. Glycemic control in type 2 diabetes: time for an evidence based about-face? Ann Intern Med 2009;150:803-8. www.annals.org\/content\/150\/11\/803.full.pdf+html","DOI":"10.7326\/0003-4819-150-11-200906020-00008"},{"key":"bibr10-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b800"},{"key":"bibr11-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.5.779"},{"key":"bibr12-aph.1M728","author":"Davidson M","year":"2000","journal-title":"Presented at: 12th International Symposium on Atherosclerosis"},{"key":"bibr13-aph.1M728","author":"Insull W","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"bibr14-aph.1M728","doi-asserted-by":"crossref","unstructured":"ShepherdJ, PackardCJ, BickerS, LawrieTDV, MorganHG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219-22. http:\/\/content.nejm.org\/cgi\/content\/abstract\/302\/22\/1219","DOI":"10.1056\/NEJM198005293022202"},{"key":"bibr15-aph.1M728","unstructured":"KuipersF, MurphyEJ. Effects of colesevelam HCl on bile acid kinetics. www.clinicaltrials.gov\/ct2\/show\/NCT00476710?term=colesevelam+HCl&rank=8 (accessed 2009 Sept 19)."},{"key":"bibr16-aph.1M728","unstructured":"VellaA. The effect of colesevelam hydrochloride (HCl) on disposition index and incretin concentrations in subjects with type 2 diabetes. www.clinicaltrials.gov\/ct2\/show\/study\/NCT00951899?term=colesevelam+HCl&recr=Open&rank=2 (accessed 2009 Sept 19)."},{"key":"bibr17-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e32831215db"},{"key":"bibr18-aph.1M728","author":"Beysen C","year":"2009","journal-title":"Presented at: 45th Annual Meeting of the European Association for the Study of Diabetes"},{"key":"bibr19-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32830c6c37"},{"key":"bibr20-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1038\/nature05449"},{"key":"bibr21-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.74.338"},{"key":"bibr22-aph.1M728","first-page":"1893","volume":"159","author":"Davidson MH","year":"1999","journal-title":"A new potent bile acid sequestrant with a low incidence of gastrointestinal side effects. Arch Intern Med"},{"key":"bibr23-aph.1M728","doi-asserted-by":"publisher","DOI":"10.4065\/76.10.971"},{"key":"bibr24-aph.1M728","doi-asserted-by":"crossref","unstructured":"SteinEA, MaraisD, SzamosiT. Colesevelam hydrochloride: efficacy and safety in pediatric patients with heterozygous familial hypercholesterolemia. J Pediatr 2009;156:231-6. http:\/\/Linkinghub.elsevier.com\/retrieve\/pii\/S002234760900804X","DOI":"10.1016\/j.jpeds.2009.08.037"},{"key":"bibr25-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00298-1"},{"key":"bibr26-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D391"},{"key":"bibr27-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1370\/afm.420"},{"key":"bibr28-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-5686-z"},{"key":"bibr29-aph.1M728","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.3.595"},{"key":"bibr30-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240610"},{"key":"bibr31-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00437-3"},{"key":"bibr32-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00638-6"},{"key":"bibr33-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.11.039"},{"key":"bibr34-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X148436"},{"key":"bibr35-aph.1M728","doi-asserted-by":"crossref","unstructured":"RiversSM, KaneMP, BuschRS, BakstG, HamiltonRA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13:11-6. http:\/\/aace.metapress.com\/Link.asp?id=v1331178816n585v","DOI":"10.4158\/EP.13.1.11"},{"key":"bibr36-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2006.08.013"},{"key":"bibr37-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000155109.69831.a3"},{"key":"bibr38-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X59157"},{"key":"bibr39-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.09.001"},{"key":"bibr40-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907569"},{"key":"bibr41-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.15.2569"},{"key":"bibr42-aph.1M728","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767100-00001"},{"key":"bibr43-aph.1M728","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2009.11.2078"},{"key":"bibr44-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.01.003"},{"key":"bibr45-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.18.1975"},{"key":"bibr46-aph.1M728","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0283"},{"key":"bibr47-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.14.1531"},{"key":"bibr48-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903126791"},{"key":"bibr49-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1089\/met.2009.0007"},{"key":"bibr50-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"bibr51-aph.1M728","doi-asserted-by":"publisher","DOI":"10.4158\/EP09146.OR"},{"key":"bibr52-aph.1M728","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u2014 2009. Diabetes Care 2009;32:S13-61. DOI 10.2337\/dc09-S013","DOI":"10.2337\/dc09-S013"},{"key":"bibr53-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2007.10.007"},{"key":"bibr54-aph.1M728","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2008.027"},{"key":"bibr55-aph.1M728","unstructured":"Package insert. Glucophage (meformin). Princeton, NJ: Bristol Myers Squibb, January 2009. http:\/\/packageinserts.bms.com\/pi\/pi_glucophage.pdf"},{"key":"bibr56-aph.1M728","volume-title":"Drug-induced disease: prevention, detection, and management","author":"Gervasio JM","year":"2005"},{"key":"bibr57-aph.1M728","first-page":"721","volume":"49","author":"Dunn CJ","year":"1995","journal-title":"A review of its pharmacological properties and therapeutic use in non\u2013insulin-dependent diabetes mellitus. Drugs"},{"key":"bibr58-aph.1M728","unstructured":"SimonsWR, HaganM. The cost effectiveness of adding colesevelam hydrochloride to metformin in patients with type 2 diabetes who have not achieved optimal glycemic control (abstract 320 1217-P). Presented at: 69th Annual Scientific Sessions of the American Diabetes Association, June 5\u20139, 2009. http:\/\/ww2.aievolution.com."},{"key":"bibr59-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2002.00223.x"},{"key":"bibr60-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00252.x"},{"key":"bibr61-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.054486"},{"key":"bibr62-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.024"},{"key":"bibr63-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.10.020"},{"key":"bibr64-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2003.07.033"},{"key":"bibr65-aph.1M728","unstructured":"RodbardH, JellingerP, DavidsonHA. Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59. www.aace.com\/pub\/pdf\/GlycemicControlAlgorithm.pdf"},{"key":"bibr66-aph.1M728","unstructured":"Joslin Diabetes Center. Joslin Diabetes Center & Joslin Clinic clinical guideline for pharmacological management of type 2 diabetes 1\/09\/2009. www.joslin.org\/Files\/Clinical-Guidelines-for-Pharmacological-Management-of-Type2-Diabetes.pdf (accessed 2009 Nov 25)."},{"key":"bibr67-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1241195"},{"key":"bibr68-aph.1M728","unstructured":"BriggsGG, FreemanRK, YaffeSJ, eds. Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2002."},{"key":"bibr69-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007831418308"},{"key":"bibr70-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A144"},{"key":"bibr71-aph.1M728","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00006"},{"key":"bibr72-aph.1M728","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00002"},{"key":"bibr73-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0312"},{"key":"bibr74-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10263"},{"key":"bibr75-aph.1M728","unstructured":"Product information. Welchol (colesevelam hydrochloride). Parsippany, NJ: Daiichi Sankyo Inc., October 2009. www.welchol.com\/pdf\/Welchol_PI.pdf"},{"key":"bibr76-aph.1M728","doi-asserted-by":"crossref","unstructured":"ItoMK, StolleySN. A matter of taste. Am J Health Syst Pharm 1999;56:80-1. www.ajhp.org\/cgi\/content\/citation\/56\/1\/80","DOI":"10.1093\/ajhp\/56.1.80"},{"key":"bibr77-aph.1M728","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20734"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1M728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:44Z","timestamp":1777374464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1M728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,15]]},"references-count":77,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1345\/aph.1M728"],"URL":"https:\/\/doi.org\/10.1345\/aph.1m728","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,15]]}}}